Kolltan Pharmaceuticals Overview
- Year Founded
-
2007
- Status
-
Acquired/Merged
- Employees
-
46
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$121M
Kolltan Pharmaceuticals General Information
Description
Developer of monoclonal antibody drugs. The company is a clinical-stage enterprise focused on discovery and development of drug candidates targeting receptor tyrosine kinases (RTKs) that impact oncology and immunology. The company's most advanced product candidates include KTN3379, a monoclonal antibody drug candidate targeting ErbB3 (HER3), which is currently in clinical development for the potential treatment of different solid tumors, and KTN0158, a monoclonal antibody targeting KIT, which is in clinical evaluation for cancer and preclinical evaluation for mast cell diseases.
Contact Information
Website
www.kolltan.comCorporate Office
- 300 George Street
- Suite 530
- New Haven, CT 06511
- United States
Corporate Office
- 300 George Street
- Suite 530
- New Haven, CT 06511
- United States
Kolltan Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 29-Nov-2016 | $121M | Completed | Clinical Trials - Phase 1 | ||
| 6. IPO | 28-Jan-2015 | Cancelled | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series D) | 17-Mar-2014 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 07-Mar-2012 | Completed | Startup | |||
| 3. Early Stage VC (Series B) | 20-Jan-2010 | Completed | Startup | |||
| 2. Grant | 31-Dec-2009 | $240K | $40M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 18-Aug-2009 | $40M | $40M | Completed | Startup |
Kolltan Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 10,000,000 | $0.001000 | $0.04 | $1.1 | $1.1 | 1x | $1.1 | 6.29% |
| Series A | 40,000,000 | $0.001000 | $1 | $1 | 1x | $1 | 27.66% |
Kolltan Pharmaceuticals Comparisons
Industry
Financing
Details
Kolltan Pharmaceuticals Competitors (73)
One of Kolltan Pharmaceuticals’s 73 competitors is BioMarin Pharmaceutical, a Formerly PE-Backed company based in San Rafael, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioMarin Pharmaceutical | Formerly PE-Backed | San Rafael, CA | ||||
| ProMIS Neurosciences | Corporation | Toronto, Canada | ||||
| Camurus | Corporation | Lund, Sweden | ||||
| Damora Therapeutics ( Drug Discovery) | Formerly VC-backed | Waltham, MA | ||||
| Nexoplex bio | Formerly VC-backed | Emeryville, CA |
Kolltan Pharmaceuticals Patents
Kolltan Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2017035430-A2 | Anti-alk antibodies and methods for use thereof | Inactive | 27-Aug-2015 | ||
| WO-2017035430-A3 | Anti-alk antibodies and methods for use thereof | Inactive | 27-Aug-2015 | ||
| WO-2016149265-A1 | Anti-met antibodies and methods of use thereof | Inactive | 16-Mar-2015 | ||
| WO-2015184231-A2 | Regulators of anaplastic lymphoma kinase and uses thereof | Inactive | 30-May-2014 | ||
| WO-2015184231-A3 | Regulators of anaplastic lymphoma kinase and uses thereof | Inactive | 30-May-2014 | A61K31/727 |
Kolltan Pharmaceuticals Signals
Kolltan Pharmaceuticals Former Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Auven Therapeutics | PE/Buyout | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| Elm Street Ventures | VC-Backed Company | Minority | ||
| Fidelity | Corporation | Minority | ||
| Gilead | Corporation | Minority |
Kolltan Pharmaceuticals Acquisitions (1)
Kolltan Pharmaceuticals’s most recent deal was a Merger/Acquisition with Xetrios Therapeutics. The deal was made on 07-Aug-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Xetrios Therapeutics | 07-Aug-2014 | Merger/Acquisition | Other Commercial Services |
Kolltan Pharmaceuticals FAQs
-
When was Kolltan Pharmaceuticals founded?
Kolltan Pharmaceuticals was founded in 2007.
-
Where is Kolltan Pharmaceuticals headquartered?
Kolltan Pharmaceuticals is headquartered in New Haven, CT.
-
What is the size of Kolltan Pharmaceuticals?
Kolltan Pharmaceuticals has 46 total employees.
-
What industry is Kolltan Pharmaceuticals in?
Kolltan Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Kolltan Pharmaceuticals a private or public company?
Kolltan Pharmaceuticals is a Private company.
-
What is the current valuation of Kolltan Pharmaceuticals?
The current valuation of Kolltan Pharmaceuticals is .
-
What is Kolltan Pharmaceuticals’s current revenue?
The current revenue for Kolltan Pharmaceuticals is .
-
How much funding has Kolltan Pharmaceuticals raised over time?
Kolltan Pharmaceuticals has raised $140M.
-
Who are Kolltan Pharmaceuticals’s investors?
Auven Therapeutics, Deerfield Management, Elm Street Ventures, Fidelity, and Gilead are 5 of 18 investors who have invested in Kolltan Pharmaceuticals.
-
Who are Kolltan Pharmaceuticals’s competitors?
BioMarin Pharmaceutical, ProMIS Neurosciences, Camurus, Damora Therapeutics ( Drug Discovery), and Nexoplex bio are some of the 73 competitors of Kolltan Pharmaceuticals.
-
When was Kolltan Pharmaceuticals acquired?
Kolltan Pharmaceuticals was acquired on 29-Nov-2016.
-
Who acquired Kolltan Pharmaceuticals?
Kolltan Pharmaceuticals was acquired by Celldex.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process